Anaphylaxis - Pipeline Review, H1 2017

  • ID: 4267376
  • Report
  • 38 pages
  • Global Markets Direct
1 of 5
Anaphylaxis - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Anaphylaxis - Pipeline Review, H1 2017, provides an overview of the Anaphylaxis (Immunology) pipeline landscape.

Anaphylaxis is a severe, potentially life-threatening allergic reaction. Anaphylaxis symptoms include dizziness, nausea, vomiting or diarrhea, feeling of warmth, constriction of the airways and a swollen tongue or throat. Risk factors include personal history of anaphylaxis, allergies or asthma and family history. Treatment includes beta-agonist, antihistamines and cortisone.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Anaphylaxis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Anaphylaxis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaphylaxis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Anaphylaxis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration and Preclinical stages are 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Anaphylaxis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Anaphylaxis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Anaphylaxis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anaphylaxis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anaphylaxis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anaphylaxis (Immunology)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anaphylaxis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anaphylaxis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5
Introduction

Anaphylaxis - Overview

Anaphylaxis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Anaphylaxis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Anaphylaxis - Companies Involved in Therapeutics Development

Adamis Pharmaceuticals Corp

MannKind Corp

Monosol Rx LLC

Anaphylaxis - Drug Profiles

epinephrine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epinephrine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epinephrine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epinephrine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ET-523 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize FcgR1 for Systemic Anaphylaxis, Autoimmune Arthritis, Pulmonary Inflammation and Thrombocytopenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize FcgRIIa for Systemic Anaphylaxis, Autoimmune Arthritis, Pulmonary Inflammation and Thrombocytopenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Anaphylaxis - Dormant Projects

Anaphylaxis - Product Development Milestones

Featured News & Press Releases

Jan 19, 2017: Adamis Announces FDA Acceptance of Resubmission of Its Epinephrine Pre-Filled Syringe NDA

Jan 10, 2017: MonoSol Rx to Initiate Human Proof-of-Concept Study of Epinephrine Sublingual Soluble Film

Dec 16, 2016: Adamis Pharmaceuticals Announces New Drug Aplication Resubmission of Its Epinephrine Pre-Filled Syringe Application to the FDA

Jun 06, 2016: Adamis Receives Complete Response Letter From FDA For Its Epinephrine Pre-Filled Syringe NDA

Jan 14, 2016: Adamis Pharmaceuticals Announces FDA Acceptance of Resubmission of Its Epinephrine Pre-Filled Syringe NDA

Dec 07, 2015: Adamis Pharmaceuticals Announces NDA Resubmission of Its Epinephrine Pre-Filled Syringe Application to the FDA

Aug 06, 2015: Adamis Pharmaceuticals Provides Regulatory Update on Its Epinephrine Pre-Filled Syringe

Mar 27, 2015: Adamis Pharmaceuticals Receives Complete Response Letter From FDA for Its Epinephrine Pre-Filled Syringe NDA

Oct 15, 2014: Adamis Pharmaceuticals Announces Key Additions to Medical and Commercial Teams

Jul 29, 2014: FDA Accepts for Review Adamis' New Drug Application for Its Epinephrine Pre-Filled Syringe

May 29, 2014: Adamis Submits New Drug Application to FDA for Its Epinephrine Pre-Filled Syringe

Sep 10, 2013: Novel Nasal Epinephrine Shows Comparable Absorption to EpiPen(R) in a Feasibility Study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Anaphylaxis, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Anaphylaxis - Pipeline by Adamis Pharmaceuticals Corp, H1

Anaphylaxis - Pipeline by MannKind Corp, H1

Anaphylaxis - Pipeline by Monosol Rx LLC, H1

Anaphylaxis - Dormant Projects, H1

List of Figures:

Number of Products under Development for Anaphylaxis, H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Adamis Pharmaceuticals Corp
  • MannKind Corp
  • Monosol Rx LLC
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll